These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20232140)

  • 21. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
    Biroccio A; D'Angelo C; Jansen B; Gleave ME; Zupi G
    J Cell Physiol; 2005 Aug; 204(2):463-9. PubMed ID: 15685647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
    Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
    Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.
    Damiano V; Garofalo S; Rosa R; Bianco R; Caputo R; Gelardi T; Merola G; Racioppi L; Garbi C; Kandimalla ER; Agrawal S; Tortora G
    Clin Cancer Res; 2009 Nov; 15(22):6921-30. PubMed ID: 19903791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.
    de Alava E; Ocaña A; Abad M; Montero JC; Esparís-Ogando A; Rodríguez CA; Otero AP; Hernández T; Cruz JJ; Pandiella A
    J Clin Oncol; 2007 Jul; 25(19):2656-63. PubMed ID: 17602072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
    Barok M; Balázs M; Nagy P; Rákosy Z; Treszl A; Tóth E; Juhász I; Park JW; Isola J; Vereb G; Szöllosi J
    Cancer Lett; 2008 Feb; 260(1-2):198-208. PubMed ID: 18096313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
    Junttila TT; Li G; Parsons K; Phillips GL; Sliwkowski MX
    Breast Cancer Res Treat; 2011 Jul; 128(2):347-56. PubMed ID: 20730488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.
    Nahta R; Takahashi T; Ueno NT; Hung MC; Esteva FJ
    Cancer Res; 2004 Jun; 64(11):3981-6. PubMed ID: 15173011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
    Mundy DW; Harb W; Jevremovic T
    Phys Med Biol; 2006 Mar; 51(6):1377-91. PubMed ID: 16510950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
    Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
    Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.
    Nahta R; Esteva FJ
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):186-90. PubMed ID: 14605867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
    Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
    Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
    Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
    Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells.
    Carpin LB; Bickford LR; Agollah G; Yu TK; Schiff R; Li Y; Drezek RA
    Breast Cancer Res Treat; 2011 Jan; 125(1):27-34. PubMed ID: 20217215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.
    Junttila TT; Parsons K; Olsson C; Lu Y; Xin Y; Theriault J; Crocker L; Pabonan O; Baginski T; Meng G; Totpal K; Kelley RF; Sliwkowski MX
    Cancer Res; 2010 Jun; 70(11):4481-9. PubMed ID: 20484044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.